Market News / Story
Zealand Pharma A/S (ZEAL) Reports Positive Phase 2 Petrelintide Results
·
Zealand Pharma A/S reported ZUPREME-2 met its primary endpoint, with up to 9.2% mean weight loss vs 2.0% placebo at 28 weeks and placebo-adjusted HbA1c reductions of 0.61%-0.88%. No unexpected safety signals; GI AE discontinuations were 1.9% vs 1.7% placebo. Material Details #DetailAI Analyst View1Up to 9.2% weight loss at 28 weeksClinically meaningful efficacy vs 2.0% placebo supports competitiveness in obesity/T2D.2Placebo-adjusted HbA1c -0.61% to -0.88%Glycemic…